Testing effectiveness (Phase 2)Ended earlyNCT00765102What this trial is testingTrial of Romidepsin and Bortezomib for Multiple MyelomaWho this might be right forMultiple Myeloma Celgene 32
Early research (Phase 1)WithdrawnNCT01680796What this trial is testingDovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma University of Florida
Large-scale testing (Phase 3)Active Not RecruitingNCT04975997What this trial is testingOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Who this might be right forMultiple Myeloma Celgene 939
Early research (Phase 1)Study completedNCT01556438What this trial is testingStudy of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple MyelomaWho this might be right forMultiple Myeloma Eli Lilly and Company 16
Large-scale testing (Phase 3)Study completedNCT00063726What this trial is testingPS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039Who this might be right forMultiple Myeloma Millennium Pharmaceuticals, Inc. 600
Early research (Phase 1)Ended earlyNCT04570631What this trial is testingStudy to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma AbbVie 4
Testing effectiveness (Phase 2)Ended earlyNCT01078441What this trial is testingBortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell TransplantWho this might be right forRefractory Multiple Myeloma National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Study completedNCT00908232What this trial is testingTreatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VDWho this might be right forMultiple Myeloma Janssen-Cilag International NV 163
Early research (Phase 1)Ended earlyNCT00590603What this trial is testingTrisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Duke University 25
Large-scale testing (Phase 3)Study completedNCT00602511What this trial is testingThalidomide Versus Bortezomib in Melphalan Refractory MyelomaWho this might be right forMultiple Myeloma Nordic Myeloma Study Group 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07614360What this trial is testingStudy of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma GlaxoSmithKline 150
Testing effectiveness (Phase 2)Study completedNCT04445701What this trial is testingStudy of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Arch Oncology 10
Large-scale testing (Phase 3)Study completedNCT02755597What this trial is testingA Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyWho this might be right forRelapsed/Refractory Multiple Myeloma AbbVie 291
Testing effectiveness (Phase 2)Study completedNCT00903968What this trial is testingCombination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Dana-Farber Cancer Institute 58
Testing effectiveness (Phase 2)Ended earlyNCT01315873What this trial is testingBortezomib and Bendamustine to Treat Relapsed/Refractory MyelomaWho this might be right forMultiple Myeloma NYU Langone Health 24
Large-scale testing (Phase 3)Active Not RecruitingNCT06208150What this trial is testingA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideWho this might be right forMultiple Myeloma Janssen Research & Development, LLC 838
Testing effectiveness (Phase 2)Study completedNCT02206425What this trial is testingIxazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsWho this might be right forMultiple Myeloma Oncotherapeutics 45
Testing effectiveness (Phase 2)Study completedNCT01168804What this trial is testingBendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Austrian Forum Against Cancer 79
Testing effectiveness (Phase 2)Study completedNCT01083602What this trial is testingEfficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple MyelomaWho this might be right forRelapsed and Bortezomib Refractory Multiple MyelomaRefractory Multiple MyelomaMultiple Myeloma in Relapse Novartis Pharmaceuticals 55
Large-scale testing (Phase 3)Study completedNCT00048230What this trial is testingPS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Millennium Pharmaceuticals, Inc. 620